Objective: Stathmin 1 is a major cytosolic phosphoprotein that regulates microtubule dynamics and is associated with malignant phenotypes in various cancers, including non-small cell lung cancer. We aimed to determine differences in overall survival and disease-free proportion in patients with lung adenocarcinoma stratified by stathmin 1 tumor expression.
See Editorial Commentary page 1418.
In recent years, efforts to improve survival have focused on the identification of targetable molecular changes within the tumor. The identification of the EGFR gene mutation in patients with lung adenocarcinoma and subsequent development of therapies targeted toward the mutation have resulted in significantly reduced hazard of death and notable survival for EGFR-gene mutation-positive patients. [1] [2] [3] [4] Efforts to improve survival in patients with EGFR wild-type gene status have been less successful. Thus, there is a continuing need to identify new and targetable molecular alterations in these patients.
Stathmin 1 (STMN1) is a cytosolic phosphoprotein that plays a crucial role in the control of cellular division and proliferation by regulating microtubule dynamics. 5 STMN1 plays an important role in a variety of biological processes, including carcinogenesis. STMN1 is highly expressed in various types of human malignancies and is also known as oncoprotein 18 . Moreover, STMN1 expression correlates with tumor progression and poor prognosis in the following cancers: gastric cancer, colorectal cancer, endometrial carcinoma, and non-small cell lung cancer (NSCLC). [6] [7] [8] [9] [10] Thus, STMN1 is a fundamental cancer-associated gene and a potential target for diagnosis and treatment. The relationship between STMN1 and survival in patients with NSCLC has been assessed in 2 prior studies, and STMN1 expression was found to be associated with poor differentiation, large tumor size, advanced N and TNM classification stages, and worse survival. 9, 10 However, these studies included only small numbers of patients, and the true impact of STMN1 expression on survival in patients with adenocarcinoma, especially in early stages, and its relationship with clinicopathologic features remain unclear.
The aim of this study is to determine the differences in overall survival (OS) and disease-free proportion (DFP) in patients with adenocarcinoma, especially in early stages, stratified by STMN1 expression and the relationship among STMN1 protein expression, clinicopathologic characteristics, mRNA expression, and driver gene mutation status.
PATIENTS AND METHODS Patients and Specimens
We analyzed 303 consecutive patients with lung adenocarcinoma who underwent complete resection with pathologically confirmed negative margins with mediastinal lymph node dissection at Gunma University Hospital (Maebashi, Gunma, Japan) between June 2003 and April 2013. No patients received chemotherapy or radiotherapy before surgery. Histologic diagnoses were made on the basis of the 4th edition of the World Health Organization criteria, and disease stage was determined according to the TNM Classification of Malignant Tumors, 7th edition. 11 The study protocol was approved by the institutional review board. All samples were used in accordance with the Helsinki Declaration after obtaining written informed consent.
We examined the patients at 3-month intervals for the first 3 years and at 3-to 6-month intervals thereafter on an outpatient basis. The follow-up duration ranged from 1 month to 12.5 years (median, 47 months). The follow-up evaluation included a physical examination, chest radiography, and blood analysis, including analysis of pertinent tumor markers. Computed tomography scans of the chest and abdomen or positron emission tomography and computed tomography were performed at least every year. Whenever any symptoms or signs of recurrence were detected, further evaluations were performed. We diagnosed recurrence on the basis of compatible physical examination and diagnostic imaging findings, and confirmed the diagnosis histologically when clinically feasible.
Immunohistochemical Staining
A 4-mm section was cut from formalin-fixed and paraffin-embedded blocks of samples. Each section was mounted on a Silane-coated glass slide, deparaffinized, and soaked for 30 minutes at room temperature in 0.3% H 2 O 2 /methanol to block endogenous peroxidases. The sections were then heated in boiled water and Immunosaver (Nishin EM, Tokyo, Japan) at 98 C for 45 minutes. Nonspecific binding sites were blocked by incubating with Protein Block Serum-Free (DAKO, Carpinteria, Calif) for 30 minutes. A mouse monoclonal anti-STMN1 (OP18) antibody (Santa Cruz 
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The Journal of Thoracic and Cardiovascular Surgery c Volume 154, Number 4 1407 Biotechnology, Santa Cruz, Calif) was applied at a dilution of 1:100 for 24 hours at 4 C. The primary antibody was visualized using the Histofine Simple Stain PO (M) Kit (Nichirei, Tokyo, Japan) according to the instruction manual. The chromogen 3,3¢ -diaminobenzidine tetrahydrochloride was applied as a 0.02% solution containing 0.005% H 2 O 2 in 50 mmol/L ammonium acetate-citrate acid buffer (pH 6.0). The sections were lightly counterstained with Mayer's hematoxylin and mounted. Negative controls were established by omitting the primary antibody. The immunohistochemical staining sections were viewed by 3 authors (K.S., Y.O., and M.A.) independently in a blind manner. Five views were examined per slide, and 100 cells were observed per view at 3200 magnification. Cells were positive for STMN1 protein when the cell cytoplasm was stained. We determined for each case a modified Allred score, 12 which is a semiquantitative system that takes into consideration the proportion of positive cells (scored on a scale of 0 to 5:
) and staining intensity (scored on a scale of 0-2: 0 ¼ none and weak, 1 ¼ intermediate, 2 ¼ strong). The proportion and intensity were then summed to produce total scores of 0 to 7. A score of 0 to 2 was classified as negative while 3 through 7 as positive ( Figure E1 ).
Mouse monoclonal antibodies against CD34 (1:800 dilution; Nichirei Corp, Tokyo, Japan) and Ki-67 (1:40; Dako, Glostrup, Denmark) were used to determine vascular formation and proliferation, respectively. The density of microvessels stained by CD34 was defined as the mean number of microvessels per 0.26-mm 2 field areas and were calculated in 4 randomly selected tumor regions at 3400 magnification; microvessel density. 13 Approximately 1000 tumor nuclei were counted on each slide, and the proliferative activity was calculated as the percentage of Ki-67-stained nuclei (Ki-67 labeling index [LI]) in each sample. The median microvessel density count was 7 (range, 1%-33%); we used 7 as the cutoff point to divide patients into high and low groups. 13 The median Ki-67 LI was 8% (range, 1%-89%), and we used 10% as the cut-off point to divide patients into high and low groups.
14 All sections were assessed independently using light microscopy in a blinded manner by 3 authors (K.S., Y.O., and M.A.). When there was any discrepancy in these staining evaluations, the final evaluation was reached by consensus.
EGFR, KRAS, BRAF, and HER2 Mutation Analysis on Extracted DNA
Immediately after surgical resection, a portion of each tumor was frozen and stored at À80 C until DNA extraction. Genomic DNA was extracted from a 3-to 5-mm cube of tumor tissue using the DNA Mini Kit (Qiagen, Hilden, Germany) and subsequently diluted to a concentration of 20 ng/mL. EGFR, KRAS, BRAF, and HER2 mutations were analyzed by peptide nucleic acids-enriched sequencing, the Eprobe method, and next-generation sequencing as described previously. 15, 16 Extraction of Total RNA and Real-Time Quantitative Polymerase Chain Reaction Total RNA was extracted from tumor tissues and the corresponding adjacent nontumor tissues using NucleoSpin RNA kit (Takara Bio Inc, Shiga, Japan) according to the manufacturer's instructions; 1 mg of total RNA 
Statistical Analysis
OS was defined as the time from the date of tumor resection to that of death from any cause or last follow-up. Patients without death were censored from the analysis at the time of the last alive follow-up, regardless of disease status. DFP was defined as the time between the date of tumor resection and the date of recurrence. All other patients censored at the time of the last negative follow-up. The chi-square test was used for univariable comparisons of background factors. STMN1 mRNA expression levels were compared between the STMN1 protein-negative and positive cases using the Student t test. Survival curves were calculated using the Kaplan-Meier method and analyzed with the log-rank test. The Cox models were used for univariable and multivariable survival analyses. To validate the use of binary STMN1 classification instead of the continuous score of the modified Allred scoring for STMN1, the Schoenfeld residuals were illustrated. To select variables for multivariable analysis, a backwardstepwise regression under Akaike's information criteria 17 was used on the total population. Any variables with P less than .05 in univariable analysis were included in the multivariable analysis. Statistical analyses were performed using SPSS software (version 21 for Windows; IBM Corp, New York, NY). The stepwise Akaike test and Schoenfeld residuals were carried out in ''R'' software, version 3.0. 
RESULTS

Stathmin 1 Protein Staining, Microvessel Density by CD34 Staining, and Ki-67 Labeling Index in Resected Adenocarcinoma
STMN1 protein expression was detected in cancer cells in tumor tissues, whereas no expression was detected in normal lung tissue or stromal cells (Figure 1 ). STMN1 expression was localized mainly to the cytoplasm of cancer cells (Figure 1 ) and was positive in 53.8% (163/303) of all patients. High microvessel density as determined by CD34 staining was detected in 52.1% of patients (158/303), and high Ki-67 LI was detected in 45.9% of patients (139/303) ( Table 1) .
Stathmin 1 protein expression and patient demographics. Patient characteristics according to STMN1 expression are shown in Table 1 . Positive STMN1 expression was significantly associated with recurrence, advanced pathologic stage, T and N statuses, poor differentiation, positive lymphatic permeation and vascular invasion, adjuvant chemotherapy, high serum carcinoembryonic antigen (CEA) level, low KRAS mutation percentage, and high microvessel density by CD34, Ki-67 LI statuses, and surgical procedure (Table 1 ). In patients with stage I disease, positive STMN1 expression also showed a statistically significant correlation with recurrence, poor differentiation, positive lymphatic permeation and vascular invasion, high serum CEA level, high microvessel density by CD34, Ki-67 LI statuses, and surgical procedure (Table 1) . We also analyzed the association between vascular invasion and microvessel density evaluated by CD34 staining. High microvessel density by CD34 was significantly associated with vascular invasion (Table E1) . Patient outcome. During follow-up, 73 patients (24.1%) died and recurrence developed in 74 patients (24.4%). The median time to cancer recurrence in the patients who had recurrence was 17.4 months. The 5-year survival for all patients was 74.6%. Figure 2 shows the Kaplan-Meier survival curves according to STMN1 expression. Patients with positive STMN1 expression had a markedly unfavorable prognosis in terms of OS and DFP (log-rank P <.001 and P <.001, respectively) ( Figure 2) . Results of the univariable and multivariable analysis are shown in Table 2 . Univariable analysis revealed that unfavorable OS was significantly associated with STMN1 expression, age, sex, smoking history, disease stage, T stage, tumor differentiation, maximum tumor size, pleural invasion, lymphatic permeation, vascular invasion, lymph node metastasis, serum CEA level, forced expiratory volume in 1 second %, EGFR mutation status, microvessel density, Ki-67 LI, and surgical procedure in all patients. We confirmed that the residuals in binary STMN1 classification were shown to be smaller than those in continuous STMN1 
scoring in Schoenfeld residuals plots in both OS and DFP ( Figure E2 ). In the multivariable Cox regression model by a backward-stepwise regression under Akaike's information criteria, STMN1 expression evaluated as binary STMN1 classification was proven to be an independent unfavorable variable for both OS (hazard ratio [HR], 2.21; 95% confidence interval [CI], 1.28-3.80) and DFP (HR, 2.02; 95% CI, 1.13-3.63) ( Table 2 ). To explore the interaction between STMN1 and recurrence with OS as the outcome, we created a new variable, coincidence of positive STMN1 expression and recurrence (STMN1*recurrence) and performed a Cox regression analysis including STMN1, recurrence (yes/no), and the interaction variable. This analysis found that only the interaction variable was an independent unfavorable prognosticator for OS (HR, 2.41; 95% CI, 1.09-5.34) ( Table 3) . Multivariable analysis by a backward-stepwise regression under Akaike's information criteria in patients with stage I also showed that STMN 1 expression was an independent unfavorable prognostic factor for DFP (HR, 2.79; 95% CI, 1.07-7.24), but marginal for OS (HR, 2.23; 95% CI, 0.95-5.22) ( Table 4) . We also performed survival analysis, grouping patients with stage I according to stage (IA or IB) and STMN1 expression status (negative or positive) and compared them with the entire group of patients with stage IB (Figure 3) . The 5-year OS and DFP of patients with stage IA with negative STMN1 expression were significantly better than those of the other groups. No patients with stage IA with negative STMN1 expression died of lung cancer (Figure 3, A) , and only 3 patients had lymphatic permeation or vascular invasion (3/80: 4.0%). In contrast, there were no significant differences in OS or DFP between those with stage IA with positive STMN1 expression and those with stage IB (Figure 3) . Correlation between stathmin 1 mRNA expression and stathmin 1 protein expression by immunohistochemical staining. We analyzed the ratio of STMN1 mRNA expression between tumor tissue and the corresponding adjacent nontumor tissue and compared the ratios of STMN1 protein-negative cases with those of positive cases. The ratios of STMN1 mRNA expression level in STMN1 protein-positive cases were significantly higher than those of negative cases by Student t test (P <.017) ( Figure E3 ).
DISCUSSION
This study demonstrated that patients with resected lung adenocarcinoma expressing STMN1 protein had worse OS and DFP compared with those whose tumors were negative for STMN1 expression by immunohistochemistry. When adjusted for other important survival indicators, STMN1 expression was an independent prognostic variable for both OS and DFP and for DFP even in the subset of patients with early-stage (stage I) disease. Furthermore, the multivariable Cox regression model, including STMN1, recurrence, and the interaction variable (STMN1*recurrence) confirmed that only the interaction variable was an independent unfavorable prognosticator for OS. These results indicated that STMN1 expression had strong interaction with recurrence, and STMN1 expression was an independent unfavorable prognostic factor for OS through interaction between STMN1 and recurrence. In other words, STMN1 expression was an independent unfavorable prognostic factor for OS in patients with recurrence.
STMN1 protein expression was associated with clinicopathologic factors, including recurrence, advanced stage, poor differentiation, positive lymphovascular invasion, high serum CEA level, high microvessel density by CD34, high Ki-67 LI, and high STMN1 mRNA level in patients with surgically resected adenocarcinoma. STMN1 expression in human cancer was reported to be invariably associated with increased local invasion, metastasis development, and poor prognosis, independently of the primary tumor histology. 18, 19 There have been no previous reports on the relationship between STMN1 protein expression and lymphatic permeation, vascular invasion, serum CEA level, microvessel density by CD34, or Ki-67 LI in NSCLC or in adenocarcinoma. Our finding that increased microvessel density was associated with poor prognosis is consistent with other studies that found that increased high microvessel density by CD34 and tumor vessel invasion was related to poor survival in stage IB to IIA NSCLC. 20 In this study, positive STMN1 protein expression, high microvessel density by CD34, and vessel invasion also were significantly related to each other. These findings suggest that STMN1 might play an important role in tumor high microvessel density and vessel invasion and therefore may be related to poor prognosis.
We demonstrated that the 5-year OS and DFP in patients with stage IA with negative STMN1 expression was 100% and 95.3%, respectively. Conversely, OS of patients with stage IA with positive STMN1 protein expression was not significantly different than OS of those with stage IB. These results suggest that STMN1-positive expression was an unfavorable prognostic factor even if their disease is in stage I.
A previous study reported that the expression level of STMN1 was negatively correlated with the efficacy of vinorelbine plus cisplatin/carboplatin therapy in advanced NSCLC. 21 Rosell and colleagues 22 found that STMN1 level affected the time to progression in vinorelbine/cisplatintreated patients. These findings suggest that STMN1 expression might correlate not only with tumor progression and metastasis but also with chemosensitivity. This would be important for thoracic oncologists in determining chemotherapeutic strategies for patients with adenocarcinoma.
Study Limitations
Our study was on a single-center cohort, and we could not perform a validation study, which may have biased our results. The second limitation is that immunohistochemical staining slides were derived from a single 4-mm section cut from each tumor block. This may have been a source of bias that might have been reduced by adding slides from a different single section. The third limitation is that we did not implement any functional studies on the relationship among STMN1 expression, metastatic potential, angiogenesis, and chemosensitivity in lung adenocarcinoma.
CONCLUSIONS
STMN1 protein expression was associated with increased tumor microvessel density and tumor progression, and patients with increased expression had worse overall prognosis (Video 1).
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